Nesiritide


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intravenous
Acutely decompensated heart failure
Adult: Initial loading dose: 2 mcg/kg by IV inj over 1 minute, followed immediately by a maintenance infusion of 0.01 mcg/kg/minute. Duration of treatment: At least 24 hr to ≥48 hr.
Hướng dẫn pha thuốc
Reconstitute a vial containing 1.5 mg of nesiritide by adding 5 ml of preservative-free diluent removed from a pre-filled 250 ml plastic IV bag (e.g. 5% Dextrose, 0.9% Sodium Chloride, 5% Dextrose and 0.45% Sodium Chloride, or 5% Dextrose and 0.2% Sodium Chloride Inj). Do not shake the vial but swirl the vial gently to ensure complete dissolution. Completely withdraw the contents of the reconstituted vial and add to the 250 ml plastic IV bag, this will produce a solution of approx 6 mcg/ml of nesiritide. Invert the IV bag several times to ensure complete mixing of the solution.
Tương kỵ
Physically and/or chemically incompatibility with heparin, insulin, sodium etacrynate, bumetanide, enalaprilat, hydralazine, furosemide and the preservative sodium metabisulfite; flush the catheter between admin of nesiritide and incompatible drugs. Do not give nesiritide through heparin-coated central catheters as it binds to heparin
Chống chỉ định
Primary therapy for cardiogenic shock; systolic BP <90 mm Hg.
Thận trọng
Not recommended in patients with known or suspected low cardiac filling pressures or in whom vasodilating agents are inappropriate (e.g. significant valvular stenosis, restrictive or obstructive cardiomyopathy, constrictive pericarditis, pericardial tamponade). Not recommended in any other conditions in which cardiac output depends on venous return. Pregnancy, lactation, children. Monitor BP closely during admin. Stop or reduce dose and general supportive measures instituted if hypotension occurs during infusion.
Phản ứng phụ
Hypotension, dizziness, headache, nausea, vomiting, abdominal pain, back pain, angina pectoris, insomnia, anxiety, renal function impairment.
IV/Parenteral: C
Quá liều
Symptoms: Excessive hypotension. Management: Reduce dose or discontinue drug. Treatment is supportive (e.g. IV fluids, changes in body position). Hypotension may persist for a few hr.
Tương tác
Increased risk of hypotension with drugs that may decrease BP.
Tác dụng
Description: Nesiritide, a biosynthetic form of human B-type natriuretic peptide (BNP), is manufactured from E. coli using recombinant DNA technology. It is structurally and pharmacologically identical to endogenous BNP, which is the main natriuretic peptide responsible for normal fluid and sodium homeostasis maintenance in heart failure patients. Binding of endogenous BNP to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells increases cyclic guanosine-3', 5'-monophosphate (cGMP), which relaxes smooth muscle cells and causes arterial and venous dilation. It also produces dose-dependent reductions in pulmonary capillary wedge pressure and systemic arterial pressure in heart failure patients.
Pharmacokinetics:
Excretion: Biphasic elimination; terminal elimination half life: 18 minutes. Removed from the circulation in 3 ways, in order of decreasing importance: Cellular uptake; proteolytic cleavage by endopeptidases and kidney excretion.
Bảo quản
Store below 25°C, do not freeze and protect from light. Reconstituted vials may be stored at 2-25°C (36-77°F) for up to 24 hr.
Phân loại MIMS
Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Nesiritide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in